Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling

First Posted Date
2010-08-05
Last Posted Date
2014-07-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
74
Registration Number
NCT01176032
Locations
🇪🇸

Novartis Investigative Site, Santander, Spain

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-06-25
Last Posted Date
2013-09-05
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
20
Registration Number
NCT01150461
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-06-24
Last Posted Date
2015-07-03
Lead Sponsor
The University of Hong Kong
Target Recruit Count
80
Registration Number
NCT01150201
Locations
🇨🇳

Queen Mary Hospital, Hong Kong, China

Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome

Phase 3
Conditions
Interventions
First Posted Date
2010-06-16
Last Posted Date
2010-08-12
Lead Sponsor
Forteza, Albert, M.D.
Target Recruit Count
140
Registration Number
NCT01145612
Locations
🇪🇸

Hospital 12 de Octubre, Madrid, Spain

🇪🇸

Hospital Vall d'Hebron, Barcelona, Spain

Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-05-14
Last Posted Date
2024-08-19
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
80
Registration Number
NCT01124175
Locations
🇨🇦

Anapharm Inc., Sainte-Foy, Quebec, Canada

Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-05-14
Last Posted Date
2010-12-08
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
80
Registration Number
NCT01124162
Locations
🇨🇦

Anapharm Inc., Montreal, Quebec, Canada

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers

First Posted Date
2010-03-16
Last Posted Date
2013-05-30
Lead Sponsor
University of California, San Francisco
Target Recruit Count
24
Registration Number
NCT01087749
Locations
🇺🇸

Clinical Reserach Center, UCSF, San Francisco,, California, United States

Anti-Fibrotic Effects of Losartan In Nash Evaluation Study

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-01-18
Last Posted Date
2015-10-07
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Target Recruit Count
45
Registration Number
NCT01051219
Locations
🇬🇧

Queen Elizabeth Hospital, Birmingham, United Kingdom

🇬🇧

Plymouth Hospitals NHS Trust, Plymouth, Devon, United Kingdom

🇬🇧

Royal Derby Hospital, Derby, United Kingdom

and more 7 locations

Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes

First Posted Date
2009-11-11
Last Posted Date
2013-10-18
Lead Sponsor
Institute for Clinical and Experimental Medicine
Target Recruit Count
23
Registration Number
NCT01011062
Locations
🇨🇿

Diabetes Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic

Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis

First Posted Date
2009-09-22
Last Posted Date
2018-11-13
Lead Sponsor
Alicia Gerke
Target Recruit Count
12
Registration Number
NCT00981747
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

© Copyright 2024. All Rights Reserved by MedPath